1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6421E8FE77B751CA700258BB00041D2D0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-more-effective-medical-affairs-product-launch-teams-infectious-diseases-segment
18
19
2018.97.14.85
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Building More Effective Medical Affairs Product Launch Teams: Infectious Diseases Segment

ID: POP-389


Features:

12 Info Graphics

32 Data Graphics

650+ Metrics

18 Narratives


Pages: 56


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Medical Affairs teams need to be agile and responsive in launching infectious disease treatments that meet evolving population health needs or public health crises. Their role is pivotal in addressing urgent clinical needs while aligning with broader public health priorities.

Best Practices, LLC conducted this benchmarking research to examine the evolving role of Medical Affairs in infectious diseases product launches, focusing on shifting responsibilities, cross-functional collaboration, performance metrics, resourcing, effectiveness of activities, launch timelines, and the use of digital tools. The report also highlights key success factors and challenges critical to achieving launch excellence in the infectious disease segment.

Industries Profiled:
Pharmaceutical; Diagnostic; Academic; Research; Health Care; Biopharmaceutical; Consulting; Biotech; Medical Device


Companies Profiled:
AstraZeneca; bioMerieux; Boehringer Ingelheim; Cardinal Health; Cipla; Duke University and Health System; Eurofarma; GlaxoSmithKline ; Labaid Group; Matinas BioPharma; MEDiSTRAVA; Melinta Therapeutics; Inc; Pfizer; Terumo BCT: Terumo Blood and Cell Technologies

Study Snapshot

Best Practices, LLC engaged 17 Medical leaders from 14 leading life sciences companies in this benchmarking research study. Medical Directors and upper management executives represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study.

Key topics covered in this report include:

  • Medical Leadership Roles and Launch Activity Effectiveness in Infectious Diseases Segment
  • Ensuring Cross-functional Alignment and Collaboration in Infectious Disease Product Launches
  • Medical Launch Evolution in Infectious Diseases Segment
  • Infectious Disease Launch Activities Timeline, Performance Tracking, and Resourcing
  • Critical Success Factors and Major Pitfalls for Medical Affairs During Infectious Disease Product Launches
  • Digital Launch Implementation and Impact in Infectious Diseases Segment
  • Launch Tool Deployment for Infectious Disease Products

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Launch Activity Effectiveness: In the infectious diseases segment, Medical Affairs drives launch success, especially through education and support. Notably, 82% of teams lead educational initiatives, with 84% rating them effective. However, only 58% lead Communication and Data Dissemination efforts, despite a 66% effectiveness rate. Organizational Support activities are led by just 45%, though 74% deem them effective. Similarly, Research leadership stands at 45%, with 77% finding it effective. These figures underscore the need for greater leadership in research and support to enhance launch impact in infectious diseases.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 4
II.
Section I: Launch Excellence and Medical’s Role & Activity EffectivenessPg. 6-12
III.
Section II: Ensuring Cross-functional Alignment and CollaborationPg. 13-15
IV.
Section III: Adopting to Ongoing Changes in Medical LandscapePg. 16-20
V.
Section IV: Launch Timeline, Preparedness Metrics, and ResourcingPg. 21-26
VI.
Section V: Critical Success Factors and Major PitfallsPg. 27-32
VII.
Section VI: Digital Influence on Launch Processes and Launch Tool DeploymentPg. 33-41
VIII.
Section VII: Participant DemographicsPg. 42-43
IX.
Section VIII: Detailed Benchmark Study DataPg. 44-55
X.
Section IX: About Best Practices, LLCPg. 56

    List of Charts & Exhibits

    I. Launch Excellence and Medical’s Role & Activity Effectiveness

    • Medical launch excellence framework
    • Medical Affairs’ role in infectious disease product launches
    • Medical leadership roles in infectious disease product launches
    • Medical Affairs’ effectiveness in infectious disease product launch activities
    • Most effective launch activities for Medical Affairs in infectious diseases segment
    • Improvement opportunities for Medical Affairs around infectious disease product launch activities

    II. Ensuring Cross-functional Alignment and Collaboration

    • Medical Affairs’ work with internal colleagues to ensure successful infectious disease product launches
    • Role of Medical Affairs group in cross-functional infectious disease product launch teams

    III. Adopting to Ongoing Changes in Medical Landscape

    • Change fronts for Medical launch evolution
    • Medical Affairs’ launch evolution around digital data dissemination and communication
    • Medical Affairs’ launch evolution around medical education
    • Medical Affairs’ launch evolution around organizational support

    IV. Launch Timeline, Preparedness Metrics and Resourcing

    • Medical Affairs’ infectious disease product launch activities timeline
    • Total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for infectious disease products during each of the years in launch phase
    • Launch dashboard and information used with the dashboard for infectious disease products
    • Percentage of total Medical Affairs launch investment allocated to each of the listed Medical Affairs activities
    • Percentage of total Medical Affairs launch FTEs allocated to each of the listed Medical Affairs activities

    V. Critical Success Factors and Major Pitfalls

    • Critical success factors for Medical Affairs in infectious disease product launches
    • Areas where advanced team planning is key for infectious disease product launches
    • Six critical areas for successful Medical Affairs launch readiness in infectious diseases segment
    • Major pitfalls for Medical Affairs during infectious disease product launches
    • Six major challenge areas for Medical Affairs during infectious disease product launches

    VI. Digital Influence on Launch Processes and Launch Tool Deployment

    • Post-pandemic digital technology utilization in Medical Affairs during infectious disease product launches
    • Impact of digital technologies on current and future infectious disease product launch processes
    • Digital launch tool deployment and impact
    • Impact of top three digital activities that Medical leads in infectious diseases segment
    • Impact of digital activities and programs used to support a successful infectious disease product launch
    • Top digital tools that can bring success to Medical Affairs product launch activities
    • Fast-growing digital tools that are impacting Medicals’ launch strategy
    • Example of a valuable digital tool that supports launch activities

    VII. Participant Demographics

    • Geographic responsibility of benchmark partners

    VIII. Detailed Benchmark Study Data

    • Role served by Medical Affairs in infectious disease product launches
    • Medical Affairs’ launch role effectiveness in infectious diseases segment
    • Role served by Medical Affairs in planning, research, and education activities in infectious diseases segment
    • Role served by Medical Affairs in data dissemination and organizational support activities in infectious diseases segment
    • Role served by Medical Affairs in research activities in infectious diseases segment
    • Role served by Medical Affairs in education and data dissemination support activities in infectious diseases segment
    • Role served by Medical Affairs in organizational support activities in infectious diseases segment
    • Medical Affairs launch activity involvement timeline - Evidence generation and field-based medical activities in infectious diseases segment
    • Medical Affairs launch activity involvement timeline - Medical information and medical regulatory activities in infectious diseases segment
    • Medical Affairs launch activity involvement timeline - HEOR activities and medical / scientific communications in infectious diseases segment
    • Medical Affairs launch activity involvement timeline - Independent medical education and external engagement activities in infectious diseases segment